Growth-hormone-derived peptide studied for effects on fat metabolism
Clinical research
Read the profile Peptide profile
Survodutide
Also known as BI 456906
Glucagon and GLP-1 receptor agonist
Clinical research
Science, with its context intact.What to knowThe evidence
The evidence
in perspective.
The cited randomized phase 2 study evaluated adults with overweight or obesity. Results concern an investigational formulation and do not establish routine clinical availability.
View the supporting source- Research area
- Metabolic
- Biological target or mechanism
- Glucagon and GLP-1 receptor agonist
- Evidence context
- Clinical research
- Availability
- Availability requires pharmacy review
From information to a conversationClinical decisions stay
Clinical decisions stay
with clinical professionals.
This profile is a research reference. Your prescriber and pharmacy assess the relevant clinical and dispensing pathway. Inclusion here is not an offer to sell this compound.
